Sodium citrate versus saline catheter locks for non-tunneled hemodialysis central venous catheters in critically ill adults: a randomized controlled trial

被引:47
作者
Hermite, Laure [2 ]
Quenot, Jean-Pierre [1 ]
Nadji, Abdelouaid [2 ]
Barbar, Saber David [1 ]
Charles, Pierre-Emmanuel [1 ]
Hamet, Mael [1 ]
Jacquiot, Nicolas [1 ]
Ghiringhelli, Francois [3 ]
Freysz, Marc [2 ]
机构
[1] Univ Bourgogne, Hop Bocage Reanimat Med, CHU Dijon, F-21079 Dijon, France
[2] Univ Bourgogne, Hop Bocage Reanimat Traumatol & Neurochirurg, CHU Dijon, F-21079 Dijon, France
[3] Univ Bourgogne, Ctr Georges Francois Leclerc, INSERM 866, F-21079 Dijon, France
关键词
Sodium citrate; Saline; Extracorporeal renal replacement therapy; Vascular access; Catheter lock; Intensive care; RENAL REPLACEMENT THERAPY; INTENSIVE-CARE-UNIT; TRISODIUM CITRATE; HEPARIN LOCK; INDUCED THROMBOCYTOPENIA; DIALYSIS CATHETERS; VASCULAR ACCESS; INFECTIONS; BACTEREMIA; PREVENTION;
D O I
10.1007/s00134-011-2422-y
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Sodium citrate has antibacterial and anticoagulant properties that are confined to the catheter when used as a catheter lock. Studies of its use as a catheter lock in chronic hemodialysis patients suggest it may be efficacious in preventing infection and thrombotic complications. We compared sodium citrate with saline catheter locks for non-tunneled hemodialysis central venous catheters in critically ill adult patients. Primary endpoint was catheter life span without complication. This was a randomized, controlled, open-label trial involving intensive care patients with acute renal failure requiring hemodialysis. Events were defined as catheter-related bloodstream infection and catheter malfunction. Seventy-eight patients were included. Median catheter life span without complication was 6 days (saline group) versus 12 days (citrate group) [hazard ratio (HR) 2.12 (95% CI 1.32-3.4), p = 0.0019]. There was a significantly higher rate of catheter malfunction in the saline group compared with in the citrate group (127 catheter events/1,000 catheter-days, saline group vs. 26 events/1,000 catheter-days, citrate group, p < 0.00001). There was no significant difference in incidence of infections between groups. We observed a significantly longer time to occurrence of infection in the citrate group (20 days vs. 14 days, HR 2.8, 95% CI 1.04-7.6, p = 0.04). By multivariate analysis, age and citrate group were the only independent factors that influenced catheter life span. This study shows for the first time that citrate lock reduced catheter complications and increased catheter life span as compared to saline lock in critically ill adults requiring hemodialysis.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 36 条
[1]
CENTRAL VENOUS CATHETERIZATION IN THE CRITICALLY ILL PATIENT [J].
AGEE, KR ;
BALK, RA .
CRITICAL CARE CLINICS, 1992, 8 (04) :677-686
[2]
Allon M, 2004, AM J KIDNEY DIS, V44, P779, DOI 10.1016/S0272-6386(04)01078-9
[4]
Current management of vascular access [J].
Allon, Michael .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (04) :786-800
[5]
Ash Stephen R, 2000, Hemodial Int, V4, P22, DOI 10.1111/hdi.2000.4.1.22
[6]
Antimicrobial lock therapy for catheter-related bacteraemia among patients on maintenance haemodialysis [J].
Bailey, E ;
Berry, N ;
Cheesbrough, JS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :615-U13
[7]
Eliminating catheter-related bloodstream infections in the intensive care unit [J].
Berenholtz, SM ;
Pronovost, PJ ;
Lipsett, PA ;
Hobson, D ;
Earsing, K ;
Farley, JE ;
Milanovich, S ;
Garrett-Mayer, E ;
Winters, BD ;
Rubin, HR ;
Dorman, T ;
Perl, TM .
CRITICAL CARE MEDICINE, 2004, 32 (10) :2014-2020
[8]
Canaud B, 1998, KIDNEY INT, V53, pS142
[9]
Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: A randomized controlled study [J].
Dogra, GK ;
Herson, H ;
Hutchison, B ;
Irish, AB ;
Heath, CH ;
Golledge, C ;
Luxton, G ;
Moody, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (08) :2133-2139
[10]
ONE-SAMPLE MULTIPLE TESTING PROCEDURE FOR PHASE-II CLINICAL-TRIALS [J].
FLEMING, TR .
BIOMETRICS, 1982, 38 (01) :143-151